BILLERICA, Mass.--(BUSINESS WIRE)--
Bruker Corporation (NASDAQ: BRKR) today announced that its Board of
Directors has approved a new share repurchase program authorizing the
purchase of up to $225 million of the Company’s common stock over a
two-year period commencing November 12, 2015.
Under the $225 million share repurchase program, the Company may
repurchase its common stock from time to time, in amounts, at prices,
and at such times as the Company deems appropriate, subject to market
conditions, legal requirements and other considerations. The Company’s
repurchases may be executed using open market purchases, privately
negotiated purchases or other transactions during the period from
November 12, 2015 to November 11, 2017.
The Company intends to fund repurchases under this share repurchase
program from cash on hand and available borrowings under its existing
credit facility. The share repurchase program does not obligate the
Company to repurchase any specific number of shares, and may be
suspended, modified or terminated at any time without prior notice.
Additionally, effective November 11, 2015, activity under the Company’s
previously announced repurchase program is suspended until January 1,
2017. Under that program, the Company is authorized to repurchase its
common stock in amounts intended to offset, on an annual basis, the
dilutive effect of shares that are or may be issued pursuant to option
awards or restricted stock grants under the Company’s long-term equity
incentive plans. Year to date through November 11, 2015, the Company
repurchased approximately 1.25 million shares for a total cost of $24.9
million under the anti-dilutive repurchase authorization.
“Our new $225 million share buyback program reflects our confidence in
the progress Bruker is making in its transformation and in its ongoing
margin expansion,” said Frank Laukien, President & CEO of Bruker. “With
a strong balance sheet and improving cash flow, we now have flexibility
to return capital to shareholders, while we continue to invest for
profitable growth.”
About Bruker Corporation
For more than 50 years, Bruker has enabled scientists to make
breakthrough discoveries and develop new applications that improve the
quality of human life. Bruker’s high-performance scientific research
instruments and high-value analytical solutions enable scientists to
explore life and materials at molecular, cellular and microscopic levels.
In close cooperation with our customers, Bruker is enabling innovation,
productivity and customer success in life science molecular research, in
applied and pharma applications, and in microscopy, nano-analysis and
industrial applications, as well as in cell biology, preclinical
imaging, clinical research, microbiology and molecular diagnostics. For
more information, please visit: http://www.bruker.com.
Forward Looking Statements
This press release contains forward-looking statements, including, but
not limited to, statements regarding the Company's commitment to
repurchasing its shares at any level in the future, the anticipated
value of shares to be repurchased by the Company, the expected timing of
such repurchases and the availability of funds for the repurchase of
shares. These forward-looking statements are based on current
information and expectations, and involve a number of risks and
uncertainties. Actual future results and/or events may differ materially
from such expectations as a result of important risk factors, which
include, in addition to those identified in the Company’s Form 10-K for
the year ended December 31, 2014 and its other filings with the
Securities and Exchange Commission: a change in the Company's share
repurchase program by the Company's Board of Directors or management,
including changes in the value of shares to be repurchased or the timing
of such repurchases, and unanticipated material payment obligations
incurred by the Company that decrease the Company's willingness or
ability to repurchase shares at the anticipated level and timing, or at
all. These risks and uncertainties could cause actual results to differ
materially from those referred to in these forward-looking statements.
The Company expressly disclaims any obligation to update or revise these
forward-looking statements, except as otherwise specifically stated by
the Company or as required by law or regulation.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151113005036/en/
Source: Bruker Corporation